Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches designed to enable the body`s immune system to fight disease. The company`s technologies are engineered to activate the immune system`s natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic disease. Immune Design`s clinical programs are the product of its two synergistic platforms: DCVexTM and GLAASTM.
-
Number of Employees:
25-100
-
Annual Revenue:
$0-1 Million